Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS to Predict Treatment Response in TNBC Patients Receiving ICI
NCT05957042Phase 1Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulfur hexafluoride in triple-negative breast cancer (TNBC), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Volume of mass on contrast enhanced ultrasound at 13 weeks, Contrast enhanced ultrasound metric-area under the curve at 13 weeks and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
sulfur hexafluoride
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05957042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957042.